Endogenous endophthalmitis in a rheumatoid patient on tumor necrosis factor alpha blocker

Indian J Ophthalmol. May-Jun 2007;55(3):230-2. doi: 10.4103/0301-4738.31951.

Abstract

The development of anti-tumor necrosis factor (TNF) therapies is a milestone in the therapy of rheumatic diseases. It is of concern whether all potential undesired complications of therapy have been evaluated within clinical trials which have led to treatment approval. Specialists prescribing TNF blockers should be aware of the unusual and severe complications that can occur. We describe a case of endogenous endophthalmitis in a rheumatoid patient on TNF alpha blocker.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy*
  • Diagnosis, Differential
  • Endophthalmitis / diagnosis
  • Endophthalmitis / microbiology*
  • Endophthalmitis / pathology
  • Eye Infections, Bacterial / chemically induced*
  • Female
  • Humans
  • Infliximab
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Ultrasonography

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab